Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KTX-1001 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Sponsors K36 Therapeutics

    • Most Recent Events

    • 12 Dec 2023 Trial design, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 04 Dec 2023 According to K36 Therapeutics media release, trial in progress data from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
    • 28 Jun 2023 According to K36 Therapeutics media release, the company will look forward to establishing KTX-1001 clinical proof of concept in multiple dosing regimens and demonstrating the expanded opportunity for KTX-1001 in additional hematologic and solid tumor malignancies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top